Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

NCT01374451 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

160

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped for not meeting the primary endpoint for PFS.

Conditions

Islet Cell Tumor

Interventions

DRUG: Everolimus
DRUG: Pasireotide LAR

Sponsor

Novartis Pharmaceuticals